https://www.sarepta.com/
Sarepta Therapeutics | Biopharmaceutical Company for Rare Diseases
We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases. Learn more about Sarepta.
sarepta therapeuticsbiopharmaceuticalcompanyrarediseases
https://www.panabee.com/company/SRPT
Sarepta Therapeutics Earnings & News | SRPT
Earnings, news, dividends, and more for Sarepta Therapeutics (SRPT). Beyond trending topics, investors can deepen their understanding of Sarepta Therapeutics...
sarepta therapeuticsearnings newssrpt
https://money.mymotherlode.com/clarkebroadcasting.mymotherlode/quote/news?ChannelType=NEWS&Symbol=NQ%3ASRPT&CurrentPage=3
Financial News | myMotherLode.com - Latest News about Sarepta Therapeutics, Inc. - Common Stock...
financial newssarepta therapeuticslatest
https://www.financialcontent.com/article/publisher/Sarepta%20Therapeutics%2C%20Inc.
Articles from Sarepta Therapeutics, Inc. | FinancialContent
View all of the latest articles from Sarepta Therapeutics, Inc.
sarepta therapeuticsarticlesinc
https://allmind.ai/earnings/event/1687466
Sarepta Therapeutics Q1 2017 Sarepta Therapeutics Inc Earnings Call | AllMind AI Earnings | AllMind...
Apr 27, 2017 - Full transcript of Sarepta Therapeutics earnings call on April 27, 2017. Q1 2017 Sarepta Therapeutics Inc Earnings Call. Read the complete earnings call...
sarepta therapeuticsearnings callincai
https://fedcircuitblog.com/en-banc/petitions/regenxbio-inc-v-sarepta-therapeutics-inc/
REGENXBIO Inc v. Sarepta Therapeutics, Inc. - Fed Circuit Blog
sarepta therapeuticsincvfedcircuit
https://www.globenewswire.com/news-release/2017/09/28/1134338/0/en/Sarepta-Therapeutics-to-Present-at-the-22nd-International-Annual-Congress-of-the-World-Muscle-Society.html
Sarepta Therapeutics to Present at the 22nd International
CAMBRIDGE, Mass., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on...
sarepta therapeuticspresentinternational
https://www.fintechworldpost.com/article/828381334-rosen-trusted-investor-counsel-encourages-sarepta-therapeutics-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel...
sarepta therapeuticsrosentrustedinvestorcounsel
https://markets.businessinsider.com/news/stocks/analysts-offer-insights-on-healthcare-companies-sarepta-therapeutics-srpt-and-livanova-livn-1035947982
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and LivaNova (LIVN) |...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT) and LivaNova (LIVN).Claim 70% Off...
healthcare companies
https://www.connecticutbusinessherald.com/article/828668035-investor-deadline-robbins-geller-rudman-dowd-llp-announces-that-sarepta-therapeutics-inc-srpt-investors-with-substantial-losses-have
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc....
https://www.businesswire.com/news/home/20240216425436/en/Sarepta-Therapeutics-Announces-U.S.-FDA-Acceptance-of-an-Efficacy-Supplement-to-Expand-the-ELEVIDYS-Indication
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS...
The U.S. FDA accepted and filed an efficacy supplement to expand the ELEVIDYS indication
https://www.arkansaspoliticalobserver.com/article/835551633-the-gross-law-firm-notifies-shareholders-of-sarepta-therapeutics-inc-srpt-of-a-class-action-lawsuit-and-an-upcoming-deadline
The Gross Law Firm Notifies Shareholders of Sarepta Therapeutics, Inc.(SRPT) of a Class Action...
https://www.sarepta.com/es/sareptassist
SareptAssist | Sarepta Therapeutics
sareptassisttherapeutics
https://politicschannelturkscaicos.com/article/835529225-sarepta-therapeutics-srpt-tanks-36-after-3rd-patient-death-srpt-securities-class-action-pending-hagens-berman
Sarepta Therapeutics (SRPT) Tanks 36% After 3rd Patient Death, SRPT Securities Class Action Pending...
https://moronipoliticalobserver.com/article/835529225-sarepta-therapeutics-srpt-tanks-36-after-3rd-patient-death-srpt-securities-class-action-pending-hagens-berman
Sarepta Therapeutics (SRPT) Tanks 36% After 3rd Patient Death, SRPT Securities Class Action Pending...
https://northdakotabusinessgazette.com/article/828668035-investor-deadline-robbins-geller-rudman-dowd-llp-announces-that-sarepta-therapeutics-inc-srpt-investors-with-substantial-losses-have
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc....
https://www.vaduzpolitics.com/article/828668035-investor-deadline-robbins-geller-rudman-dowd-llp-announces-that-sarepta-therapeutics-inc-srpt-investors-with-substantial-losses-have
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc....
https://worldpoliticsvirginislands.com/article/828668035-investor-deadline-robbins-geller-rudman-dowd-llp-announces-that-sarepta-therapeutics-inc-srpt-investors-with-substantial-losses-have
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc....
https://cureduchenne.org/articles/sarepta-therapeutics-reports-long-term-outcomes-through-168-weeks-from-phase-iib-study-of-eteplirsen-in-duchenne-muscular-dystrophy-2/
Sarepta Therapeutics Reports Long-Term Outcomes through 168 Weeks from Phase IIb Study of...
Jan 12, 2015 - Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced data through Week 168 from Study 202, a Phase IIb...